Clinical Trial Update: Clinical Trial Comparing a Biosimilar Eptacog Alfa With Novoseven, in Patients With Hemophilia With Inhibitors [Phase 3]

View source ↗

Summary

Phase 3 clinical trial comparing a biosimilar Eptacog alfa with NovoSeven in patients with hemophilia A or B with inhibitors has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia with Inhibitors

Drugs mentioned

• NovoSeven (recombinant coagulation factor VIIa)
• biosimilar Eptacog alfa (eptacog alfa biosimilar)

Snippet

Sponsor: AryoGen Pharmed Co. | Conditions: Hemophilia A or B With Inhibitor | Phase 3 | Status: COMPLETED